<DOC>
	<DOC>NCT02996240</DOC>
	<brief_summary>Assess the impact of dietary omega 3 free fatty acids breast cancer patients.</brief_summary>
	<brief_title>Breast, Omega 3 Free Fatty Acid, Ph 0</brief_title>
	<detailed_description>Prospective, single arm, short term study with correlative biomarker endpoints. Two hundred (200) newly diagnosed breast cancer patients will be recruited to participate in a short term (30 day) Phase 0 biomarker evaluation study prior to surgical resection. Patients will be receive fish Oil (Omega-3 FFAs, 2700 mg by mouth twice daily).</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>At least 18 years of age ECOG â‰¤2 Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee Consented for tissue collection on CTRC repository 0732 Active systemic illness (infection including viral illnesses such as Hepatitis and HIV) Chronic use of NSAIDs or omega3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days) Any NSAIDs or omega3 free fatty acid supplementation within the last 14 days History of medical noncompliance Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>